Methods for the Construction of Recombinant Oncolytic Myxoma Viruses

Lino E. Torres-Domínguez, Ana Lemos de Matos, Masmudur M. Rahman, Grant McFadden

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Myxoma virus (MYXV) has proven to be an effective candidate for oncolytic virotherapy in many preclinical cancer models. As a nonhuman pathogen, MYXV does not need to overcome any preexisting antiviral immunity, and its DNA cannot integrate into the host genome, making it an extremely safe vector. Moreover, the large dsDNA genome of MYXV allows the insertion of multiple transgenes and the design of engineered recombinant oncolytic viruses (OVs) with enhanced immunostimulatory or other desired properties. In this chapter, we describe detailed protocols for the generation and characterization of transgene-armed recombinant MYXV vectors.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Number of pages13
StatePublished - 2021

Publication series

NameMethods in Molecular Biology
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029


  • Armed oncolytic virus
  • Engineered virus
  • Myxoma virus
  • Oncolytic virotherapy
  • Oncolytic virus
  • Poxvirus
  • Recombinant virus
  • Viral vector

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics


Dive into the research topics of 'Methods for the Construction of Recombinant Oncolytic Myxoma Viruses'. Together they form a unique fingerprint.

Cite this